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A great variety of compounds are formed during lipid peroxidation of polyunsaturated
fatty acids of membrane phospholipids. Among them, bioactive aldehydes, such as
4-hydroxyalkenals, malondialdehyde (MDA) and acrolein, have received particular attention
since they have been considered as toxic messengers that can propagate and amplify
oxidative injury. In the 4-hydroxyalkenal class, 4-hydroxy-2-nonenal (HNE) is the most
intensively studied aldehyde, in relation not only to its toxic function, but also to its
physiological role. Indeed, HNE can be found at low concentrations in human tissues
and plasma and participates in the control of biological processes, such as signal
transduction, cell proliferation, and differentiation. Moreover, at low doses, HNE exerts
an anti-cancer effect, by inhibiting cell proliferation, angiogenesis, cell adhesion and by
inducing differentiation and/or apoptosis in various tumor cell lines. It is very likely that
a substantial fraction of the effects observed in cellular responses, induced by HNE and
related aldehydes, be mediated by their interaction with proteins, resulting in the formation
of covalent adducts or in the modulation of their expression and/or activity. In this review
we focus on membrane proteins affected by lipid peroxidation-derived aldehydes, under
physiological and pathological conditions.
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INTRODUCTION: LIPID PEROXIDATION-DERIVED
ALDEHYDES
Reactive intermediates produced under conditions of oxidative
stress cause the oxidation of polyunsaturated fatty acids (PUFAs)
in membrane lipid bilayers, leading eventually to the formation
of aldehydes (Esterbauer et al., 1991). Among these, the most
abundant aldehydes are 4-hydroxy-2-nonenal (HNE) and mal-
ondialdehyde (MDA), while acrolein is the most reactive one
(Esterbauer et al., 1991). HNE is the lipoperoxidation prod-
uct which has displayed the highest biological activity and, for
this reason, has been most intensively studied. On the other
hand, acrolein, which is the most electrophylic compound, has
received less attention, because it is scarcely represented among
lipoperoxidation products. Both acrolein and HNE are α,β-
unsaturated electrophilic compounds, which preferentially form
1,4-Michael type adducts with nucleophiles, such as proteins
and DNA. Even though MDA shows little reactivity under phys-
iological conditions, at low pH its reactivity increases, when
beta-hydroxyacrolein becomes the predominant species and,
analogously to acrolein and HNE, it can form 1,4-Michael type
adducts with nucleophiles (Esterbauer et al., 1991). Even though
it was demonstrated that MDA does not react with glycine and
GSH, and reacts slowly with cysteine (Esterbauer et al., 1991)
under physiological conditions, cellular proteins are much more
readily modified by MDA (Chio and Tappel, 1969).
Due to the high chemical reactivity of aldehydes, mammals
have evolved a battery of enzymes which convert these com-
pounds to less reactive chemical species. The main reactions
of aldehydes are the adduction with glutathione (GSH), which
can either occur spontaneously or be catalyzed by glutathione
S-transferases (GSTs), the reduction to alcohol by aldo–keto
reductases (AKRs) or alcohol dehydrogenase and the oxidation to
acid by aldehyde dehydrogenases. The metabolism of aldehydes
has been reviewed in excellent mode by Esterbauer and collab-
orators (1991). More recent reviews were focused on the bio-
chemistry of lipid peroxidation products (Guéraud et al., 2010)
and acrolein biotransformation (Stevens and Maier, 2008). The
catabolic rates of the various aldehydes contribute, together with
their rates of production from lipid peroxidation, in determining
their steady-state intracellular concentrations. At high concentra-
tions, all these aldehydes were found to play a role in the toxic
effects of lipid peroxidation. Aldehyde toxicity is mainly due to the
alterations of several cell functions, which mostly depend on the
formation of covalent adducts with cellular proteins (Grimsrud
et al., 2008). Due to their amphiphilic nature, aldehydes can easily
diffuse across membranes and can covalently modify any protein
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in the cytoplasm and nucleus, far from their site of origin (Negre-
Salvayre et al., 2008). Similarly, the aldehydes formed outside the
cells (i.e., in a site of inflammation or in plasma), can react with
adjacent cells, even in cases when they are not primary sites of
lipid peroxidation. In the latter instance, plasma membrane pro-
teins represent the first targets for adduct formation. Exogenous
or endogenous aldehydes can react also with nuclear proteins,
thus modulating protein expression through their reaction with
transcription factors or other regulatory elements (Jacobs and
Marnett, 2010). The targets of lipid peroxidation-derived alde-
hydes are cell-type specific and dependent both on the pattern
of proteins expressed by the cell and the aldehyde concentration.
Moreover, the modification of a specific protein can have different
biological consequences, in relation to its specific cell function.
However, at low concentration, HNE in particular can play an
important role in signal transduction and exert antiproliferative
and anti-invasive actions toward cancer cells, by interfering with
the modulation of gene expression via the formation of protein
and/or DNA adducts (Gentile et al., 2009; Barrera, 2012).
The presence of aldehyde-protein adducts has been demon-
strated in a wide range of physiological and pathological con-
ditions. Those among the latter in which aldehyde-protein
adducts, in particular HNE-protein adducts, have been most
intensively studied are neurodegenerative diseases and atheroscle-
rosis. Recently, a role has emerged for aldehyde-protein adducts
in autoimmune diseases, since the covalent alteration of protein
structure can bring about a sufficient modification of a self anti-
gen for it to break the immunological tolerance of autoreactive
T and/or B cells. In the following sections, we shall examine
the mechanisms of formation of aldehyde-protein adducts and
the main biological consequences of the formation of aldehyde
adducts with membrane proteins in neurodegenerative diseases,
atherosclerosis, autoimmune diseases and in relation with the
functions played by cell proteins at the plasma membrane level.
The chemical structures of HNE, MDA and acrolein are illus-
trated in Figure 1
CHARACTERISTICS OF ALDEHYDES AND THEIR PROTEIN
ADDUCTS
4-HYDROXYNONENAL (HNE)
4-Hydroxynonenal (HNE) is an aldehyde highly represented
among the products of lipid peroxidation, which displays high
biological activity. This aldehyde has three main functional
groups: the aldehyde group, the C=C double bond and the
FIGURE 1 | Structures of 4-hydroxy-2-nonenal (HNE), malondialdehyde
(MDA) and acrolein.
hydroxyl group, which can participate, alone or in sequence, in
chemical reactions with other molecules (Esterbauer et al., 1991).
Due to its strong hydrophobic nature, HNE is mostly associated
with the membranes where it is produced, but it can also diffuse
to different cellular compartments (Butterfield and Stadtman,
1997). HNE is a highly electrophilic molecule that easily reacts
with glutathione, proteins and, at higher concentration, with
DNA. HNE forms adducts with three different amino acyl side
chains, namely of Cys, His, and Lys residues, via Michael addi-
tion either to thiol (−SH) or to amino (−NH2) groups. Cys
residues display the highest reactivity with HNE, even though Cys
residues are not always the preferential targets of HNE, because
the tertiary structure of the protein can condition their accessi-
bility and, therefore, their reactivity toward exogenous chemicals.
No reaction of HNE was detected with Glu (Doorn and Petersen,
2003). Besides by the simple formation of Michael adducts to
lysyl, histidyl, and cysteinyl residues (Esterbauer et al., 1991),
HNE can modify protein structure through Schiff base forma-
tion with lysyl residues, leading to pyrrole formation (Sayre et al.,
1996). In addition, HNE modification can result in the cross-
linking of two lysyl residues through reversibly formed Schiff base
Michael adducts (Parola et al., 1999; Xu et al., 1999), as well as
irreversibly formed 2-hydroxy-2-pentyl-1,2-dihydropyrrol-3-one
iminium moieties (Parola et al., 1999; Dianzani, 2003; Barrera
et al., 2008). The target proteins of HNE adduct formation in vitro
and in vivo have been reviewed in great detail by Poli et al. (2008).
HNE has been detected in vivo in several pathological con-
ditions characterized by increased lipid peroxidation, including
inflammation, atherosclerosis, chronic degenerative diseases of
the nervous system, and chronic liver diseases (Moreau et al.,
2005).
ACROLEIN
Acrolein is a little aldehyde with three carbon atoms and a double
bond. Besides being formed endogenously during lipid perox-
idation, this aldehyde is inhaled with cigarette smoke and is
present in cooked oils and other foods (Stevens andMaier, 2008).
Acrolein is the strongest electrophile in the α,β-unsaturated alde-
hyde series; its reaction with the thiol group of cysteine was about
110–150 times faster than that of HNE (Esterbauer et al., 1991;
Witz, 1997). The toxicity of acrolein is related to its ability to
deplete glutathione (Kehrer and Biswal, 2000), and to form DNA
and protein adducts (Esterbauer et al., 1991; Sanchez et al., 2005;
Feng et al., 2006). Potential targets of acrolein in proteins include
the side chains of cysteinyl, histidyl, and lysyl residues, as well as
free N-terminal amino groups (Cai et al., 2009). Cysteine is widely
accepted as the most likely site of acrolein adduct formation.
The sulfhydryl group of a cysteinyl residue is the most reac-
tive nucleophile in proteins and the thiol adducts with acrolein
are considerably more stable than the adducts formed by other
α,β-unsaturated aldehydes (Esterbauer et al., 1991; Witz, 1997).
Cysteinyl residues are located at the active sites of several proteins
and are often involved in the catalytic activity of enzymes, thus
the formation of acrolein-cysteine adducts has broad functional
implications. It has been reported that the modification of cys-
teinyl residues by acrolein leads to the inactivation of enzymes,
such as aldose reductase (Srivastava et al., 1999) and protein
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tyrosine phosphatase 1B (Seiner et al., 2007). However, no cys-
teine adducts of acrolein have been identified in vivo. Other
Authors have shown that acrolein generated during lipid perox-
idation may primarily react with histidyl residues of proteins, to
form Nτ-(3-propanal)-histidine and that acrolein-histidine is the
major adduct formed with proteins in in vitro studies (Maeshima
et al., 2012).
Elevated plasma concentrations of acrolein are detected in
patients with chronic renal failure, and the abundance of the pro-
teins adducts of acrolein is increased in tissues obtained from
patients with Alzheimer’s disease, Parkinson’s disease, atheroscle-
rosis and chronic obstructive lung disease (Uchida et al., 1998a;
Shamoto-Nagai et al., 2007; Stevens and Maier, 2008; Moretto
et al., 2012).
MALONDIALDEHYDE (MDA)
Malondialdehyde (MDA) is widely used as a marker for the per-
oxidation of ω3 and ω6 fatty acids, measured by the chemical
determination of thiobarbituric acid reactive substances (TBARS)
(Negre-Salvayre et al., 2010), although the latter provides an
incomplete perspective, as MDA derives from the decompo-
sition of only certain lipid peroxidation products and is nei-
ther the sole end product, nor one of lipid peroxidation only
(Halliwell and Whiteman, 2004). At neutral pH, MDA is present
as enolate anion, with low chemical reactivity (Esterbauer et al.,
1991). Nevertheless, it is able to interact with nucleic acid
bases to form several different adducts (Marnett, 1999). MDA
has been reported to react in vivo with primary amines, to
form Nε-(2-propenal) lysine and generate lysine-lysine cross-
links with 1-amino-3-iminopropene and pyridyledihydropyri-
dine type bridges (Uchida, 2000). These reaction products have
been detected in Apo B fractions of oxidized lipoproteins (LDL)
and are thought to be involved in the impaired interaction of
modified lipoproteins with macrophages (Palinski et al., 1994).
Mooradian and coworkers have reported that protein glycosyla-
tion and the presence of acetaldehyde enhanceMDAmodification
of proteins (Mooradian et al., 1996, 2001). Moreover, MDA and
acetaldehyde can form stable adducts (MAA) (Tuma et al., 1996)
and can react covalently and synergistically with proteins, form-
ing MAA–protein adducts. The latter can be pro-inflammatory
and pro-fibrogenic and are capable of inducing strong immune
responses (Tuma, 2002).
PHOSPHATIDYL γ-HYDROXYALKENALS (PC-HAs)
Phosphatidylcholine γ-hydroxyalkenals (PC-HAs) are the most
abundant and biologically relevant compounds in the class of
γ-hydroxyalkenal phospholipids, deriving from the peroxidation
of polyunsaturated fatty acids (PUFAs) esterified to phospho-
glycerides at the sn-2 position of phosphatidylcholine (PC).
β-Scission of an alkoxyl radical derived from dihydroperox-
ide produces two γ-hydroxy-α,β-unsaturated aldehydes, i.e., a
methyl-terminal HNE molecule and a mirror image of HNE,
still esterified to PC (namely, 9-hydroxy-12-oxo-10-dodecenoic
acid [HODA] or its PC ester from linoleate and 5-hydroxy-8-
oxo-6-octenoic acid [HOOA] or its PC ester from arachidonate).
Because they possess a γ-hydroxy-α,β-unsaturated terminal alde-
hyde like HNE, PC-hydroxyalkenals are expected to formMichael
adducts with primary amino groups of lysyl residues and thiol
groups of cysteinyl residues, as well as pentylpyrrole adducts,
incorporating the ε-amino groups of lysyl residues (Figure 2). γ-
Hydroxyalkenal phospholipids contribute strongly in the patho-
genesis of the atherosclerotic disease. ω-Carboxyalkylpyrrole
modifications of proteins, after lypolysis of intermediate phos-
pholipid adducts, are of pathogenetic importance in age-related
macular degeneration, autism and cancer, and promote wound
healing. In regard, the reader is referred to the excellent reviews
by Salomon et al. (2011), and Salomon and Gu (2011).
ALDEHYDE-PROTEIN ADDUCTS IN NEURODEGENERATIVE
DISEASES
Central nervous system (CNS) is one of the major targets of
lipid peroxidation. The brain is highly sensitive to oxidative
stress because it consumes about 20–30% of inspired oxygen and
contains high levels of PUFAs. In particular, high levels of the
markers of lipid peroxidation have been found in brain tissues
and body fluids in several neurodegenerative diseases, including
Alzheimer’s disease (AD), Parkinson disease (PD), amyotrophic
lateral sclerosis (ALS), Huntington disease (HD) and Down syn-
drome (DS) (Sajdel-Sulkowska and Marotta, 1984; Butterfield
et al., 2010; Ruiperez et al., 2010; Lee et al., 2011; Shichiri et al.,
2011). We focus here on the adducts of lipid peroxidation-derived
aldehydes with protein targets whose oxidative modifications
might be relevant for the neuronal dysfunctions observed in
Alzheimer’s disease.
ALZHEIMER’S DISEASE (AD)
Oxidative damage occurs in early stages of Alzheimer’s dis-
ease (AD) (Butterfield et al., 2006a; Reed et al., 2008, 2009a;
Mangialasche et al., 2009). Several Authors, using redox pro-
teomic approaches, have undertook the task of compiling inven-
tories of cellular proteins modified as a consequence of increased
oxidation, glycoxidation, or lipoxidation in the course of oxidative
and/or nitrosative stress (Pamplona et al., 2005; Butterfield et al.,
2006b; Newman et al., 2007; Reed et al., 2008, 2009a,b; Perluigi
et al., 2009). Other searches focused upon proteins modified by
tyrosine nitration (Castegna et al., 2003; Sultana et al., 2006a;
Reed et al., 2008) and S-glutathionylation (Newman et al., 2007).
A number of comprehensive reviews are available (Mangialasche
et al., 2009; Martínez et al., 2010; Reed, 2011; Sultana et al.,
2012). Like in other neurodegenerative diseases with proteina-
ceous deposits, vulnerable proteins could be assigned to a few
distinct functional groups with crucial roles in plasmamembrane
ion and nutrient transport, energy metabolism (glycolysis, mito-
chondrial electron transport and oxidative phosphorylation), cell
signaling, cytoskeletal organization, antioxidant defenses, cellu-
lar stress responses, protein synthesis, signal transduction, and
regulation of neurotransmission (Table 1).
HNE-Amyloid β peptide adducts
Amyloid β (Aβ) peptide is the major protein component of amy-
loid plaques and one of the main components of neurofibrillary
tangles (NFTs), hallmarks of AD. This molecule is a 40-to-42-
amino acid peptide derived from the integral membrane Amyloid
Precursor Protein (APP), through sequential proteolytic cleavages
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FIGURE 2 | Structures and reactions of phosphatidylcholine
γ-hydroxyalkenals (PC-HAs). In addition to 2-pentylpyrrole-modification of
proteins by the electrophilic addition of HNE to ε-amino lysyl groups,
carboxyalkylpyrrole-modified proteins are also formed by adduct formation
with other γ-hydroxyalkenals (mirror images of esterified HNE) also formed,
at the time of HNE formation, from the oxidation of PUFA-containing
phospholipids. Legend: HHE, 4-hydroxy-2-hexenal; HNE, 4-hydroxy-2-nonenal;
PL-PC, 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine; PA-PC,
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine; PD-PC,
1-palmitoyl-2-docosahexanoyl-sn-glycero-3-phosphocholine; HODA-PC,
9-hydroxy-12-oxo-10-dodecenoyl-phosphatidylcholine (this compound may
also derive from 1-linoleoyl-2-arachidonoyl-sn-glycero-3-phosphocholine,
LA-PC); HOOA-PC, 5-hydroxy-8-oxo-6-octenoyl-phosphatidylcholine;
HOHA-PC, 4-hydroxy-7-oxo-5-heptenoyl-phosphatidylcholine; PP-protein,
2-pentylpyrrole-modified protein; EP-protein, 2-ethylpyrrole-modified protein;
CPP-protein, carboxypropylpyrrole-modified protein; CEP-protein,
carboxyethylpyrrole-modified protein [Reprinted with permission from
Salomon et al. (2011)].
by β-secretase (BACE) and γ-secretase (Hardy and Selkoe, 2002).
HNE can react directly with the Aβ peptide. This process was
reported to exacerbate the formation of toxic Aβ-dependent
diffusible oligomers and insoluble aggregates, which, in turn,
enhanced oxidative stress, fromation of lipid peroxidation prod-
ucts, such as HNE, and Aβ oligomerization and toxicity (Siegel
et al., 2007). HNE modified the three histidyl residues of Aβ,
so that HNE-modified Aβ molecules had increased affinities for
membrane lipids and adopted a similar conformation as mature
amyloid fibrils (Murray et al., 2007; Liu et al., 2008).
HNE-α-enolase adducts
α-Enolase (non neural enolase, ENO1) is a multiform, multifunc-
tional protein. In the cytoplasm, it is a 48-kDa enzyme, catalyzing
2-phospho-D-glycerate dehydration to phosphoenolpyruvate. At
the cell surface of neutrophils, B and T cells, monocytes, epithe-
lial, endothelial cells and neurons, it serves as a plasminogen
receptor, involved in fibrinolysis (Pancholi, 2001) and in neu-
trophil andmonocyte recruitment (Busuttil et al., 2004;Wygrecka
et al., 2009). Binding to α-enolase protects plasmin from inac-
tivation by α2-antiplasmin (Bergman et al., 1997). Alternative
translation of α-enolase mRNA produces a 37-kDa protein, pref-
erentially located in the nucleus (myc Binding Protein-1, MBP-1),
with c-myc gene promoter-binding and tanscription repressing
activity (Feo et al., 2000; Subramanian and Miller, 2000). In
addition, α-enolase was reported to be a hypoxic stress pro-
tein (Graven and Farber, 1998). A regulatory circuit between
c-myc, MBP-1, and α-enolase was described, connecting cell
energy metabolism and proliferation (Sedoris et al., 2007). Redox
proteomic studies identified α-enolase as a target of oxida-
tive modification in all stages of Alzheimer’s disease, undergo-
ing the formation of carbonyl groups (Castegna et al., 2002;
Butterfield et al., 2006b; Sultana et al., 2006b), MDA adducts
(Pamplona et al., 2005), 4-HNE adducts (Reed et al., 2008, 2009a;
Perluigi et al., 2009), tyrosine nitration (Castegna et al., 2003;
Sultana et al., 2006a; Reed et al., 2009b) and S-glutathionylation
(Newman et al., 2007). A typical metabolic feature of AD is the
reduced rate of glucose metabolism, as seen in positron-emission
tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG/PET)
(de Leon et al., 2001). Despite compensatory increases of α-
enolase expression in AD (Sultana et al., 2007) and even though
enzymatic activity was not assayed, it was suggested that the
loss of function associated with the oxidative modifications of
α-enolase might render neurons prone to apoptosis, by dysrupt-
ing their energy metabolism (Sultana et al., 2012). As peptide
Aβ(1-42), by aggregating in cross-β-structured fibrils, with a sim-
ilar conformation as fibrin peptides, could substitute for fibrin
in the activation of tissue plasminogen activator (tPA) (Kingston
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Table 1 | HNE-protein adducts detected in Alzheimer’s disease, in relation with disease progressiona.
Protein AD stagea Function References
Aldolase PAD, LAD Energy metabolism Perluigi et al., 2009
Triose phosphate isomerase (TPI) EAD Energy metabolism Reed et al., 2009a
Phosphoglycerate kinase (PGK) MCI Energy metabolism Reed et al., 2008
α-Enolase (non neural enolase, ENO1)b MCI, EAD,
LAD
Energy metabolism Reed et al., 2008, 2009a;
Perluigi et al., 2009
Pyruvate kinase (PK) M2 isoform PAD, MCI Energy metabolism Reed et al., 2008
Lactate dehydrogenase B (LDHB) MCI Energy metabolism Reed et al., 2008
Aconitase PAD, LAD Energy metabolism, mitochondrial function Perluigi et al., 2009
Malate dehydrogenase, mitochondrial EAD Energy metabolism, mitochondrial function Reed et al., 2009a
ATP synthase α subunit PAD, MCI,
EAD, LAD
Energy metabolism, mitochondrial function Reed et al., 2008, 2009a;
Perluigi et al., 2009
Mn Superoxide dysmutase (SOD2) EAD, LAD Mitochondrial function, antioxidant defense Perluigi et al., 2009; Reed
et al., 2009a
Carbonyl reductase 1 MCI Antioxidant defense Reed et al., 2008
Peroxiredoxin VI (Phospholipase A2) LAD Antioxidant defense Perluigi et al., 2009
Heme oxygenase 1 (HO-1) MCI, LAD Antioxidant defense Sultana et al., 2012
70-kDa heat shock protein (HSP70) MCI Stress response Reed et al., 2008
Pleckstrin homology-like domain, family A, member 2 (IPL) Signal transduction Reed et al., 2008
β-Actin MCI Cytoskeleton Reed et al., 2008
α-Tubulin LAD Cytoskeleton Perluigi et al., 2009
Elongation factor Tu (EF-Tu) PAD, MCI Protein synthesis Reed et al., 2008
Initiation Factor α (eIFα) MCI Protein synthesis Reed et al., 2008
Glutamine synthetase LAD Excitotoxicity Perluigi et al., 2009
Neuropolypeptide h3 PAD, MCI Neuronal communication Reed et al., 2008
Collapsin response mediated protein 2 (CRMP-2)c EAD, LAD Neuronal communication Perluigi et al., 2009; Reed
et al., 2009a
aClinical stages of Alzheimer’s disease (AD) progression, in chronological order: PAD, preclinical AD; MCI, mild cognitive impairment; EAD, early stage AD; LAD, late
stage AD.
bIntegral or perypheral membrane proteins of plasma or organelle membranes are underlined.
cAlso known as dihydropirimidinase-related protein 2 (DRP-2).
et al., 1995), and because plasmin cleaved peptide Aβ1-40 into
a truncated form, with potent stimulatory activity toward tPA
(VanNostrand and Porter, 1999), it was proposed that the loss
of plasminogen-binding activity of HNE-α-enolase might foster
apoptosis in AD, by hindering Aβ peptide degradation (Sultana
et al., 2012).
Such a scenario is supported by a functional study of HNE-
α-enolase adducts in HL-60 leukemic cells (Gentile et al., 2009).
α-Enolase was among a few proteins recognized by anti-histidine-
HNE antibodies, after 15min of exposure to 1–10μM HNE.
HNE–α-enolase adducts were detected early on the surface of HL-
60 cells, indicating a high degree of α-enolase exposure. HNE
treatment did not alter α-enolase expression or enzymatic activ-
ity. The low-level expression of an anti-α-enolase Ab-reactive
37-kDa peptide, possibly corresponding to MBP-1, did not vary
after HNE treatment. The main functional alteration of HNE-
α-enolase concerned its plasminogen-binding ability. Treatment
with 1μM HNE strongly inhibited plasminogen binding to α-
enolase at the cell surface and consequently reduced HL-60 cell
adhesion to human umbilical venous cells (HUVECs), suggesting
that HNE and other inhibitors of plasminogen binding to α-
enolase may be of use in the control of tumor invasion. α-Enolase
emerged from this study as a protein most susceptible to HNE
adduct formation, in keeping with various proteomic studies, in
the context of neurodegeneration, cited in section Alzheimer’s
Disease (AD), which pinpointed a limited number of protein tar-
gets of oxidative modification, including α-enolase, grouped in
selected functional subsets (Martínez et al., 2010; Reed, 2011;
Sultana et al., 2012). Some of these proteins targets were also iden-
tified as autoantigens frequently recognized by autoantibodies in
autoimmune diseases. α-Enolase, in particular, was recurrently
indicated as a novel autoantigen in systemic lupus erythemato-
sus (SLE), systemic sclerosis (SSc) (Moscato et al., 2000; Pratesi
et al., 2000; Mosca et al., 2006; Bussone et al., 2011), SSc with
interstitial lung fibrosis (Terrier et al., 2010), rheumatoid arthritis
(Goëb et al., 2009; Saulot et al., 2002), mixed cryoglobuline-
mia (MC) with nephropathy (Sabbatini et al., 1997; Moscato
et al., 2000; Pratesi et al., 2000), pulmonary arterial hyperten-
sion (Bussone et al., 2012), giant-cell arteritis (Régent et al.,
2011), Behçet’s disease (Lee et al., 2003) and inflammatory bowel
disease (IBD) (Roozendaal et al., 1998). Anti-α-enolase autoan-
tibodies isolated from patiens with SLE, SSc and MC recog-
nizedmembrane-associated α-enolase and inhibited plasminogen
binding to it (Moscato et al., 2000). It is tempting to speculate
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that the high susceptibility of α-enolase to modification by HNE
and other aldehydes might be instrumental for its involvement
in autoimmunity as an oxidatively modified self antigen, capable
of breaking the immunological tolerance of autoreactive T and
B cells. This is in keeping with the identification of α-enolase
among the proteins undergoing carbonyl addition and HNE
adduction in heart homogenates and cardiomyocytes oxidized
in vitro with 4-HNE or H2O2. Oxidative modifications correlated
with increased recognition of α-enolase by serum antibodies of
rodents and humans affected with Chagas’ disease, which is char-
acterized by increased production of ROS of inflammatory and
mitochondrial origin (Dhiman et al., 2012).
HNE adducts with other neuronal enzymes, transporters, and
receptors
Inducible heme oxygenase 1 (HO-1) catalyzes heme conversion to
biliverdin-IXa, which is further reduced to antioxidant bilirubin-
IXa (Mancuso and Barone, 2009). The expression of the HO-1
gene is redox-regulated by an antioxidant responsive element
in its promoter. Activation of HO-1 contributes to the adaptive
response to oxidative stress in AD (Poon et al., 2004). Increased
levels of HO-1 were observed in association with neurofibrillary
tangles (NFTs) and senile plaques (Takeda et al., 2000) and in
hippocampal neurons of AD patients, together with increases of
serine phosphorylation, tyrosine nitration and 4-HNE modifica-
tion of HO-1, as though adaptive increases in HO-1 expression
and activation were counteracting the structural and functional
impairment of HO-1, via tyrosine nitration and HNE-HO-1
adduct formation.
Collapsin response mediator protein 2 (CRMP2). Participates in
axon guidance and synapse maturation, by mediating the trans-
duction of reelin (Yamashita et al., 2006) and semaphorin 3A
signals (Uchida et al., 2009). Sultana et al. (2012) has proposed
that the HNE-CRMP2 adducts (Reed et al., 2008; Perluigi et al.,
2009) might be of pathogenic importance for neurite shortening
and the loss of synapses, early features of AD (Hensley et al., 2011;
Scheff et al., 2011), and that Aβ peptide-induced oxidation of pep-
tidylprolyl cis/trans isomerase (Pin1) (Butterfield et al., 2006b;
Sultana et al., 2006b) may be responsible for the dysregulation
of glycogen synthase kinase-3β (GSK-3β) and cyclin-dependent
kinase 5 (CDK5) and for the hyperphosphorylation of tau pro-
teins and of colocalized CRMP2 within NFTs (Williamson et al.,
2011).
Reduced glucose utilization and energy production (Rhein
and Eckert, 2007) are early occurrences in AD. They may be
explained by the reported formation of HNE adducts with neu-
ronal glucose transporter GLUT3 in rat hippocampal neurons
(Mark et al., 1997a) and with the mitochondrial ATP synthase
α subunit in human AD brains (Reed et al., 2008; Perluigi et al.,
2009; Terni et al., 2010). Decreased levels of ATP synthase activity
were also reported in AD (Schagger and Ohm, 1995). Soluble Aβ
peptide oligomers were responsible for electron-transport chain
dysruption, enhanced ROS generation, mitochondrial fragmen-
tation, and synaptic damage (Reddy et al., 2010), as well as for
enhanced HNE production (Mark et al., 1997b). ATP synthase
α subunit was colocalized with CRMP2 within NFTs (Sergeant
et al., 2003). In AD brains, LDL receptor-related protein 1 (LRP-
1), a membrane receptor involved in Aβ peptide removal, was
also covalently modified by HNE, which might contribute to the
extracellular deposition of amyloid substance (Owen et al., 2010).
Acrolein-protein adducts
Acrolein is neurotoxic in vitro. Moreover, in Alzheimer’s brains,
high levels of acrolein were detected in hippocampus and tempo-
ral cortex, where oxidative stress is high (Dang et al., 2010). Thus,
several studies addressed the mechanism of acrolein neurotoxic-
ity. Dang and coworkers (2010) showed that, in neuronal primary
cultures of hippocampal cells, acrolein exerted more toxic effects
than HNE. This might depend on the higher reactivity of
acrolein, which was an initiator of oxidative stress by forming
adducts with cellular nucleophilic groups in proteins, lipids, and
nucleic acids. Indeed, it was documented that in synaptosomal
proteins, exposed to high concentrations of acrolein, a loss of
thiol group content occurred, due to Michael adduct formation
between acrolein and thiol groups of proteins (LoPachin et al.,
2007). Moreover, such adduct formation led also to protein
cross-linking. Based on the cited evidence, LoPachin et al. (2002,
2003) proposed that nerve terminals were the primary sites of
acrolein action and that synaptic dysfunction was a necessary step
in the production of neurotoxicity. In support of this hypothesis,
in vivo and in vitro studies showed that exposure to acrolein was
associated with reduced presynaptic neurotransmitter release.
This effect involved inhibition of key proteins, which regulate
membrane–vesicle fusion, such as N-ethylmaleimide-sensitive
fusion protein (NSF) and synaptosomal-associated protein of
25 kDa (SNAP-25) (Barber and LoPachin, 2004; LoPachin, 2004).
Acrolein also inhibited presynaptic membrane neurotransmitter
uptake and vesicular storage in vivo and in vitro (LoPachin et al.,
2006; LoPachin, 2004). Proteomic analyses showed that these
dysfunctions were associated with the formation of adducts with
the dopamine transporter and v-ATPase, respectively Barber
and LoPachin, 2004; LoPachin, 2004; LoPachin et al., 2007;
Barber et al., 2007. In vitro studies showed that acrolein and HNE
disrupted synaptosomal membrane protein conformation and
phospholipid asymmetry (Subramaniam et al., 1997; Pocernich
et al., 2001; Castegna et al., 2004), reduced glutamate uptake
and GLUT3-mediated glucose transport in synaptosomes and
cultured nerve cells (Keller et al., 1997a,b; Lovell et al., 2000),
reduced respiration and induced oxidative stress in synaptosomal
mitochondria (Humphries et al., 1998; Morel et al., 1999; Picklo
et al., 1999; Picklo and Montine, 2001; Luo and Shi, 2005; Raza
and John, 2006), inhibited membrane Na+ and Ca2+ ion pumps
and dysrupted ion regulation in cultured nerve cells (Keller et al.,
1997b; Mark et al., 1997b).
MDA-protein adducts
A largely coincident protein repertoire as the one delineated
by anti-HNE antibodies was compiled by the immunochem-
ical detection of Nε-MDA-lysine. It included: α- (non neu-
ral) and γ-enolase (neural), glutamic acid dehydrogenase I,
creatin kinase B chain (CKB), ubiquinol-cytochrome c reduc-
tase complex core protein I, ATP synthase β subunit, glu-
tathione synthase (GS), 60-kDa heat shock protein (HSP-60),
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guanine nucleotide-binding protein G(I)/G(S)/G(T) β subunit 2
(GNB2), β- and γ-actin, α- and β-tubulin, vimentin, neurofila-
ment L, glial fibrillar acidic protein (GFAP), collapsin response
mediator protein 2, CRMP2, DRP-2) (Pamplona et al., 2005),
and 14-3-3 protein ζ (HYWAZ) and γ (HYWAG) isoforms
(Santpere et al., 2007).
A redox model of Alzheimer’s disease pathogenesis
Far beyond individual protein dysfunctions, the generation of
markers of lipid peroxidation in AD appears to be associated
with the progressive endangerment of vital processes, such as
energy metabolism, antioxidant defenses, signal transduction,
axonal transport, and synapse conservation. A redox model of
Alzheimer’s disease pathogenesis (Sultana et al., 2012) is depicted
in Figure 3.
FIGURE 3 | A redox model of Alzheimer’s disease pathogenesis.
Amyloid β-peptide (Aβ) is generated by proteolytic cleavage of Amyloid
Precursor Protein (APP) by secretases. Aβ undergoes aggregation, with the
formation of oligomers, which undergo a conformational transition to
β-structured diffusible oligomers and eventually deposit as amyloid plaques
in the ECM. Aβ oligomers insert in the plasma membrane, where they
initiate lipid peroxidation, leading to the formation of reactive aldehydes,
such as acrolein, MDA and HNE. Adduct formation compromises the
function of critical proteins in a number of functional subsets of
neurotransmission, energetic metabolism, mitochondrial function,
antioxidant defenses, represented here by collapsin response mediated
protein 2 (CRMP2), α-enolase, ATP synthase α subunit and heme
oxygenase 1. Such process is self-feeding and ultimately leads to
Alzheimer’s disease [Redrawn with permission from Sultana et al. (2012)].
ALDEHYDE-PROTEIN ADDUCTS IN ATHEROSCLEROSIS
The potential role of reactive aldehydes in the pathogenesis of
atherosclerosis was suggested by their increases in plasma in asso-
ciation with extensive aortic atherosclerosis and the high levels
of aldehydes generated during the oxidation of phospholipids
in LDLs (Salomon et al., 2000). The observed consequences
of LDL oxidation by aldehydes in vitro are described below.
The formation of protein-bound lipid peroxidation products in
atherosclerotic lesions was also repeatedly reported.
ALDEHYDE-LDL ADDUCTS
Early studies of the contribution of aldehyde-protein adducts to
atherogenesis provided evidences that modification of LDL by
aldehydes enhanced their recognition and uptake bymacrophages
(Hoff et al., 2003). The formation of aldehyde adducts with
apolipoprotein B (Apo B) in LDL converted the latter to an
atherogenic form that was taken up by macrophages, lead-
ing to the formation of foam cells (Steinberg et al., 1989;
Steinberg, 1995). The adduction products detected in Apo B of
oxidized LDL included: (a) acrolein derivatives, such as N-(3-
methylpyridinium)lysine (MP-Lys) (Obama et al., 2007) and the
3-formyl-3,4-dehydropiperidino adduct (FDP-lysine) formed by
the addition of two acrolein molecules to one lysyl side chain
(Uchida et al., 1998a,b); (b) HNE adducts, such as the enaminal-
type HNE-histidine and HNE-lysine adducts (Uchida et al.,
1994); (c) MDA adducts, such as Nε-(2-propenal)-lysine (Uchida
et al., 1997), and 1-amino-3-iminopropene-type MDA-lysine
cross-links (Requena et al., 1997). The formation of aldehyde-
LDL adducts could alter the binding of LDL to membrane scav-
enger receptors at the surface of endothelial cells and activated
macrophages. The participation of reactive aldehydes in LDL-
receptor interactions was documented by several immunohisto-
chemical analyses of atherosclerotic lesions from human aorta,
using antibodies against various aldehyde adducts, such as HNE-
histidine (Uchida et al., 1995), Nε-MDA-lysine (Uchida et al.,
1997), and Nε-acrolein-lysine (FDP-lysine) (Uchida et al., 1998a),
in which intense positivities were associated with cells, primar-
ily macrophages. It was recently reported that HNE–histidine
Michael adducts had significant affinities and interacted with
LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1),
an important scavenger receptor mediating endothelial oxLDL
uptake. HNE-modified proteins strongly inhibited the uptake
of acetylated LDL (AcLDL). In human aortic endothelial cells,
the binding of HNE-histidine adducts to LOX-1 stimulated ROS
formation and activated extracellular signal-regulated kinase 1/2
(ERK 1/2) and NF-κB (Kumano-Kuramochi et al., 2012).
Using recombinant human Apo E (an exchangeable
antiatherogenic apolipoprotein) and immunoblotting with
acrolein-lysine-specific antibodies, other Authors (Tamamizu-
Kato et al., 2007) showed that acrolein severely compromised
the functional integrity of Apo E, as for heparin, lipid, and LDL
receptor binding. These results were in agreement with previous
observations of acrolein being widely present in atherosclerotic
lesion, as revealed by the use of anti-acrolein antibodies (Uchida
et al., 1998a). Nε-(3-methylpyridinium)-lysine (MP-Lys), an
acrolein derivative, was detected in Apo B of native LDL
(Obama et al., 2007). Moreover, acrolein-LDL induced foam
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cell formation from macrophages, suggesting that acrolein
maight contribute to LDL modification, foam cell formation and
atherogenesis (Watanabe et al., 2013).
PHOSPHATIDYLCHOLINE γ-HYDROXYALKENALS AND
ATHEROSCLEROSIS
Starting from the early observation that proteins modified by
2-pentylpyrrole incorporation of lysyl ε-amino groups, upon
covalent addition of HNE, accumulated in the blood of individ-
uals with atherosclerosis and in brain neurons of patients with
Alzheimer’s disease (Sayre et al., 1996), it became evident that
γ-hydroxyalkenal phospholipids and their ω-carboxyalkylpyrrole
derivatives contributed strongly in the pathogenesis of atheroscle-
rosis. This was the subject of recent reviews (Salomon and Gu,
2011; Stemmer and Hermetter, 2012). Antibody-based studies
revealed the presence of carboxyethylpyrroles (CHPs) and
carboxypropylpyrroles (CPPs) in oxLDL (Kaur et al., 1997). Also
the CHP immunoreactivity, reflecting the presence of protein
adducts of 9-hydroxy-12-oxo-10-dodecenoic acid (HODA) or
its phosphatidylcholine ester in human plasma, was significantly
higher in the plasma of patients with atherosclerosis and end-
stage renal disease than in healthy controls (Kaur et al., 1997).
HODA-protein adducts were produced in vivo from 9-hydroxy-
12-oxo-10-dodecenoyl-phosphatidylcholine (HODA-PC), one
of the oxidized lipids derived from 1-palmityl-2-arachidonoyl-
sn-glycero-3-phosphocholine (PA-PC), altogether referred to as
oxPA-PC. Chemically synthesized 5-hydroxy-8-oxo-6-octenoyl-
phosphatidylcholine (HOOA-PC) exhibited properties of a
chemical mediator of chronic inflammation. It activated, in
a dose-dependent manner, human aortic endothelial cells to
bind monocytes and to secrete increased levels of monocyte
chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8), two
chemokines promoting monocyte entry into chronic lesions. It
also inhibited LPS-induced expression of E-selectin, an adhe-
sion molecule mediating endothelial-neutrophil interactions
(Subbanagounder et al., 2002). HOOA-PC was found unbound
and in pyrrole adducts in lipid extracts of oxLDL and human
atheromas (Podrez et al., 2002; Hoff et al., 2003). A scenario
emerged from these studies, in which atherogenesis might involve
myeloperoxidase-initiated, free radical-induced production of
oxPC, which promoted subendothelial monocyte infiltration and
endocytosis of oxLDL by macrophages, accompanied by conver-
sion into foam cells and atheroma formation (Salomon and Gu,
2011). Thereafter, it was shown that scavenger receptor CD36,
another mediator of oxLDL uptake by macrophages, at variance
with the LDL receptor, bound oxidized lipid derivatives within
oxLDL, including the derivatives of 1-palmitoyl-2-arachidonoyl-
glycerophosphocholine (oxPA-PC), such as HOOA-PC, and of
1-linoleoyl-2-arachidonoyl-glycerophosphocholine (oxLA-PC),
such as HODA-PC (Figure 2). These γ-oxygenated-α,β-
unsaturated aldehydes, collectively referred to as oxPCCD36,
were potent activators of the CD36-mediated endocytosis of
oxLDL by macrophages, promoting the cytotoxic effects of the
formation of protein adducts of electrophilic oxidized derivatives
of cholesterol and phospholipids (Salomon and Gu, 2011). As
an instance, the formation of Michael or pyrrole adducts of
HOOA-PC or HODA-PC to a cysteinyl thiol group of lysosomal
cathepsin B reduced the ability of mouse macrophages to degrade
internalized macromolecules (Hoff et al., 2003). OxLDL and
individual oxPCCD36 also interfered with the binding of HDL
to scavenger SR-B1 receptors of hepatocytes, thus inhibiting the
HDL-mediated delivery of cholesteryl esthers to the liver (Ashraf
et al., 2008).
HNE-SCAVENGER RECEPTOR B1 ADDUCTS AND KERATINOCYTE HDL
UPTAKE
Scavenger Receptor B1 (SR-B1), also known as HDL receptor,
is expressed in cells of the epidermal stratum corneum. In cul-
tured human keratinocytes, exposure to cigarette smoke caused
the translocation and eventual loss of SR-B1, driven by the acti-
vation of cellular NADPH oxidase (NOX) and the enhanced
H2O2 production. Cigarette smoke also caused the formation
of acrolein-SR-B1 and HNE-SR-B1 adducts and increased SR-B1
ubiquitination. It was proposed that such oxidation-dependent
modifications of SR-B1 subcellular localization and stability
might affect the physiological uptake of cholesterol by SC epider-
mal cells, which, in turn, might compromise their lipid composi-
tion and barrier function in the course of oxidative stress (Sticozzi
et al., 2012).
ALDEHYDE-PROTEIN ADDUCTS IN AUTOIMMUNITY
Modification of self antigens in the course of oxidative stress,
by adduct formation with reactive products of lipid peroxida-
tion, HNE being one of the most commonly involved, is generally
regarded to as a mechanism by which concomitant modifica-
tion of self and neoantigen formation may lead to the breaking
of tolerance to self antigens and, thus, to the pathogenesis of
autoimmune disease. Indeed, it was known for a long time that
abnormally high levels of HNE-protein adducts can be detected
in the sera of children affected by autoimmune diseases (Grune
et al., 1997). According to this view, cross-linking ofHNEwith self
antigens would be instrumental in creating neoantigens from for-
merly tolerated autoantigens and, thus, initiating autoimmunity.
HNE-PROTEIN ADDUCTS IN SJÖGREN’S SYNDROME (SS) AND
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sjögren syndrome (SS) is an autoimmunity-driven chronic
infammatory disorder, characterized by infiltration and destruc-
tion of lacrimal and salivary glands by effector CD4+ and CD8+
T cells and activated macrophages, resulting in keratoconjunc-
tivitis with dry eyes and xerostomia (dry mouth). Secondary SS
can also add to the clinical picture of other autoimmune diseases,
such as systemic lupus erythematosus (SLE). Among autoim-
mune diseases, SS is second only to rheumatoid arthritis (RA) in
prevalence (1%), with affected females outnumbering males by
9–1. Antibodies to self antigens, such as anti-nuclear antibodies
(ANA), are characteristically found in SS, some of them being in
common with other autoimmune diseases, such as SLE, RA, and
systemic sclerosis (SSc). Typical ANA targets in SS include the SS-
A/Ro and SS-B/La proteins. The former include a 52-kDa form,
located in nucleus and in cytoplasm, (SS-A1/Ro52; TRIM21)
and a 60-kDa cytoplasmic form (SS-A2/Ro60; TROVE2). Both
are components of Ro ribonucleoprotein (RNP) particles, in
which they associate with short non-coding, histidine-rich RNAs
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(hY-RNAs). The 48-kDa SS-B/La antigen is a transcription ter-
mination factor for RNA Polymerase III, transiently associated
with hY-RNAs in ribonucleoprotein particles involved in tRNA
processing and histonic mRNA stabilization. Systemic lupus ery-
thematosus (SLE) is a multisystemic disease characterized by
a polyclonal B cell activation, leading to the differentiation of
plasma cells producing autoantibodies toward a broad range of
autoantigens. ANA are found in 95% of patients with SLE, as well
as in patients with other autoimmune diseases. They are heteroge-
neous and include antibodies toward: double stranded (ds) DNA;
histones; ribonucleoproteins (RNP), such as the Smith (Sm) anti-
gen (corresponding to the common core proteins of spliceosomal
small nuclear RNPs), and the SS-A/Ro and SS-B/La antigens. The
formation and deposition of immune complexes and comple-
ment in the wall of small arteries, at the dermo-epidermal junc-
tion and in the glomerular basalmembrane (GBM) is responsible,
respectively, for the diffuse necrotizing vasculitis, the cutaneous
lesions of erythematous, bullous, and ulcerative kind, and the
nephritis associated with SLE.
Notwithstanding their nuclear and/or cytoplasmic location,
Ro and La antigens appeared to become exposed at the cell
surface in the course of apoptosis. Epitopes expressed at the
surface of apoptotic cells are named “apotopes.” After the first
observations of the clustering of cytoplasmic and nuclear anti-
gens, including SS-Ro and SS-La antigens, in two types of blebs
at the surface of apoptotic cells (Casciola-Rosen et al., 1994),
the accessibility of SS-A/Ro and SS-B/La antigens at the sur-
face of apoptotic cells was further confirmed (Miranda-Carús
et al., 2000; Ohlsson et al., 2002). In SLE and SS, both the num-
ber of circulating apoptotic leukocytes and the susceptibility of
lymphocytes to activation-induced apoptosis in vitro increased
(Emlen et al., 1994; Georgescu et al., 1997; Zeher et al., 1999;
Ren et al., 2003). Impaired efferocytosis (clearance of apoptotic
cells) by macrophages also contributed to the higher degree of
exposure to autoantigens determined by the increased rate of
apoptosis in SLE (Ren et al., 2003). It was speculated that both
factors may trigger autoimmunity (Savill et al., 2002). It was
proposed (Casciola-Rosen et al., 1994) that the breaking of tol-
erance to autoantigens at the surface of apoptotic cells might be
favored by oxidative modifications occurring as a result of the
oxidative stress that characterizes apoptosis (Hockenberry et al.,
1993).
The contribution of the formation of HNE adducts to the
modification of self antigens, such as SS-A2/Ro60, in Sjögren’s
syndrome was explored by Scofield and coworkers. They hypothe-
sized that modification of SS-A2/Ro60 with HNE might facilitate
the breaking of tolerance to the self antigen. After immunizing
rabbits with either HNE-modified or unmodified SS-A2/Ro60,
they observed that autoimmunity was established faster and
more strongly in animals immunized with HNE-modified SS-
A2/Ro60 (Scofield et al., 2005). In an extension of this model,
an SS-like condition, with anti-SS-A2/Ro60 antibodies, decreased
salivary flow and salivary gland mononuclear infiltrates, could
be induced in BALB/c mice by immunization with a peptide of
SS-A2/Ro60 (Kurien et al., 2011). Efficient production of anti-SS-
A2/Ro60 and anti-SS-B/La autoantibodies ensued immunization
with SS-A2/Ro60, both as such and modified with increasing
concentrations of HNE (0.4, 2, or 10mM). However, antibody
production was faster after low- and medium-level modifica-
tion of SS-A2/Ro60 with HNE. Differential use of unmodified
or HNE-modified SS-A2/Ro60 as the solid-phase substrate in
ELISAs for autoantibodies revealed, among the antibodies pro-
duced by mice immunized with HNE-modified SS-A2/Ro60, an
additional subpopulation of antibodies, which recognized HNE
or HNE-SS-A2/Ro60, but not unmodified SS-A2/Ro60. Most
interestingly, immunization with medium-level HNE-modified
SS-A2/Ro60 was accompanied by the appearance of anti-dsDNA
autoantibodies, which induced the Authors to imply a SLE-like
disease, although they did not provide pathological evidence
of it. Together with the already mentioned appearance of anti-
SS-B/La antibodies, following immunization with SS-A2/Ro60,
the occurrence of anti-dsDNA antibodies represented an exam-
ple of intermolecular epitope spreading. In turn, the ability of
HNE to form adducts with a large number of biological macro-
molecules could be of help in understanding the broad range of
autoantibody responses in SLE and SS. Moreover, immunization
with high-level HNE-modified SS-A2/Ro60 was associated with
weaker antibody responses to unmodified SS-A2/Ro60 and SS-
B/La, reduction of salivary flow and lymphocytic infiltration of
salivary glands, suggesting a Sjögren’s syndrome-like condition.
Notably, high-level HNEmodification of SS-A2/Ro60 was accom-
panied by aggregation, which prompted the Authors to interpret
the results as due to increasing bifunctional cross-linking of
SS-A2/Ro60 and diminished exposure of HNE at the surface
of SS-A2/Ro60 molecules (Kurien et al., 2011). A more likely
interpretation could be that large, particulate immunocomplexes
of aggregated HNE-SS-A2/Ro60 and autoantibodies stimulated
the phagocytic and antigen-presenting activity of macrophages,
which skewed the autoimmune response toward a prevailingly
cytotoxic cell-mediated mechanism.
The molecular mimicry between the adducts of lipid peroxida-
tion products with proteins and nucleic acids, as a possible mech-
anism initiating the production of anti-DNA autoantibodies, in
response to some other modified self antigen, was the subject of
interesting studies by Uchida and coworkers. After raising an anti-
HNE monoclonal antibody (anti-R mAb 310), recognizing enan-
tioselectively (R)-HNE-histidine Michael adducts (Hashimoto
et al., 2003), they unexpectedly found that the sequence of this
anti-HNE mAb was highly similar to those of various clonally
related anti-DNA antibodies. Despite these structural similarities,
the cross-reactivity of mAb R310 with native dsDNA was lim-
ited, but was strongly enhanced by treating DNA with 4-oxo-2-
nonenal (ONE), a HNE analog. The 7-(2-oxo-heptyl)-substituted
1,N2-etheno-type ONE-2’-deoxynucleoside adducts were identi-
fied as alternative epitopes of mAb R310 in ONE-modified DNA.
On these grounds, these Authors hypothesized that endogenous
reactive electrophiles, like HNE, might function as immuno-
logic triggers for human autoimmunity (Akagawa et al., 2006).
These Authors further investigated the possible involvement of
HNE-modified proteins as the endogenous source of anti-DNA
antibodies. They found HNE-specific epitopes in the epider-
mis and dermis of patients with SLE, pemphigus vulgaris and
contact dermatitis, as well as antibodies against HNE-modified
bovine serum albumin (BSA) in the sera of patients affected with
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SLE, Siögren’s syndrome, rheumatoid arthritis, systemic sclero-
sis and idiopathic inflammatory miopathies, and also in the sera
of diseased MRL/lpr mice. Upon repeated immunization with
HNE-modified KLH, mice developed also a subpopulation of B
cell clones recognizing native DNA, but not HNE-BSA. In agree-
ment with previous results, the reactivity of anti-HNE B cell
clones toward DNA was greatly enhanced by DNA modification
with ONE. On the other hand, anti-DNA mAbs cross-reacted
with ONE-modified BSA. These data suggested that HNE-specific
epitopes produced upon physiological generation of HNE in
cells might serve as triggering antigens for the development
of bispecific antibodies against native DNA and ONE-modified
proteins. On the whole, these findings strongly supported the
pathogenic role of lipid peroxidation products in autoimmune
disease (Toyoda et al., 2007). The pathogenic role of lipid per-
oxidation in SLE and the potential usefulness of anti-MDA and
anti-HNE antibody titers in predicting its progression was under-
scored also by a report showing that the prevalences and serum
levels ofMDA- andHNE-protein adducts, as well as ofMDA- and
HNE-specific antibodies, were significantly higher in SLE patients
than in healthy controls, and were in correlation with the SLE
Disease Activity Index. The levels of each aldehyde-protein adduct
were also in correlation with the titers of the respective antibodies
(Wang et al., 2010).
ALDEHYDE-PROTEIN ADDUCTS AND STRUCTURAL
INTEGRITY, ION TRANSPORT, AND SIGNAL TRANSDUCTION
AT THE PLASMA MEMBRANE LEVEL
HNE is the product of lipid peroxidation which has been shown
to be mostly involved in the control of cell functions. Under phys-
iological conditions, HNE can be found at low concentrations in
human tissues and plasma (Parola et al., 1998; Okada et al., 1999;
Ji et al., 2001; Siems and Grune, 2003), where it participates in
the control of signal transduction, cell proliferation and differen-
tiation (Parola et al., 1998). HNE-protein adducts in peripheral
blood primarily involve albumin, transferrin and immunoglobins
(Barrera et al., 1996). Adducts between HNE and proteins have
been detected in vitro in various mammalian cell types (Parola
et al., 1998; Okada et al., 1999; Ji et al., 2001; Siems and Grune,
2003), in which the percent of total added HNE in HNE-protein
adducts was between 1 and 5% (Rinaldi et al., 2001). Some
adducts of HNE with cell proteins involved in specific functions
at the plasma membrane level were characterized in detail.
HNE-SPECTRIN ADDUCTS AND RED CELL MEMBRANE INTEGRITY
Spectrin is the main component of the submembranous
cytoskeleton lining the intracellular side of the plasma membrane
of red blood cells, playing a fundamental role in maintaining
its stability and strength, via direct interactions with membrane
lipids and the actin cytoskeleton. Immunoblotting andmass spec-
trometric analyses revealed that, in human red cells, α- and
β-spectrin were the primary targets of HNE adduction. Exposure
of intact red cells to HNE resulted in selective HNE-spectrin
adduct formation, with preferential β-spectrin modification and
cross-linking of HNE-modified spectrin molecules. The Authors
speculated that local spectrin aggregation, by freeing the lipid
bilayer from the underlying spectrin-actin cytoskeleton, might
lead to membrane surface area loss by extrusion (Arashiki et al.,
2010). Together with the reported accumulation of HNE in aging
circulating red blood cells (Ando et al., 1995), these observations
may be of relevance not only for the physiological destruction of
aged red cells, but also for the immune-mediated hemolysis of
red blood cells under conditions of enhanced production of lipid
hydroperoxides.
HNE-Na+-K+-ATPase ADDUCTS
Na+-K+-ATPase is an integral plasmamembrane protein of great
functional importance. Its primary functions are the mainte-
nance of intracellular K+ ion levels and the excretion of Na+
ions. It contains 70 cysteinyl residues per molecule. The bind-
ing of HNE at 1–10μmolar concentration to Na+-K+-ATPase
was rapid and was accompanied by a decrease in measurable SH-
groups and an irreversible loss of enzyme activity (Siems et al.,
1996). Na+-K+-ATPase could be attacked by HNE formed both
intra- and extracellularly, due to the free access of HNE to inte-
gral plasmamembrane proteins. These Authors suggested that the
reduction of Na+-K+-ATPase activity upon covalent HNE bind-
ing might represent an important form of secondary oxidative
cell damage. Their findings were confirmed by the demonstration
that in cultured hippocampal neurons HNE impaired Na+-K+-
ATPase activity and induced increases of intracellular Ca2+ ion
concentration (Mark et al., 1997b).
HNE ADDUCTS WITH TYROSINE KINASE RECEPTORS
Tyrosine kinase receptors (RTKs), such as the epidermal growth
factor receptor (EGFR) and the platelet-derived growth fac-
tor receptor (PDGFR), are transmembrane glycoproteins, dis-
playing tyrosine kinase activity in their cytoplasmic domains.
Stimulation of RTKs by ligand-dependent or -independentmech-
anisms (radiation, metal ions, ROS) induces receptor dimeriza-
tion and autophosphorylation of tyrosyl residues, followed by
catalytic activation, whereas downregulation of RTKs is medi-
ated by internalization and dephosphorylation (Pawson and
Scott, 1997). Oxidized LDL (but not native LDL) and free HNE
induced in living cells the formation of HNE-EGFR and HNE–
PDGFR adducts, evidenced by the binding of anti-HNE-protein
antibodies and by the loss in free −NH2 group content (Suc
et al., 1998; Hubbard and Till, 2000; Escargueil-Blanc et al.,
2001). At physiological ormoderate HNE concentrations (0.1μM
and 1–10μM), the formation of HNE-EGFR and HNE-PDGFR
adducts resulted in sustained RTK activation (Suc et al., 1998;
Escargueil-Blanc et al., 2001). A short incubation of vascular
smooth muscle cells (SMCs) with a low concentration of HNE
(0.1–1μM) induced the derivatization and autophosphorylation
of RTKs, with the consequential activation of the phosphatidyli-
nositol 3-kinase (PI3K)/Akt-mediated survival pathway and of
the mitogenic response of SMCs (Auge et al., 2002). On the
other hand, high concentrations of HNE, for longer incubation
times, inhibited EGFR- and PDGFR-mediated cell proliferation
(Liu et al., 1999; Vindis et al., 2006), through inhibitory effects
on RTK signaling (Negre-Salvayre et al., 2003). High doses of
HNE exerted similar negative effects on proteasomes (Okada
et al., 1999; Vieira et al., 2000), mitochondrial transition pores
(Irwin et al., 2002), glyceraldehyde-3-phosphate dehydrogenase
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(Uchida and Stadtman, 1993) and cathepsin B activities (Crabb
et al., 2002). The inhibitory effect of 4-HNE on growth
factor-dependent cell proliferation was in agreement with the
progressive desensitization of PDGFR β subunit to its ligand
PDGF B-chain in SMCs (Vindis et al., 2006). In other cell types,
low HNE concentrations (1μM) did not cause RKT activa-
tion. In human hepatic stellate cells (hHSC), 1μM HNE rather
inhibited tyrosine autophosphorylation of PDGFR β induced
by the PDGF BB isoform, which resulted in the inhibition of
the mitogen-activated protein kinase (MAPK) and PI3K cas-
cades and a consequential decrease of PDGF-dependent DNA
synthesis (Robino et al., 2000). Acrolein was also shown to
be a potent inactivator of protein tyrosine phosphatase 1B
(PTP1B), a member of an important class of cysteine-dependent
enzymes, working in tandem with protein tyrosine kinases in
the regulation of a number of signal transduction pathways
(Seiner et al., 2007).
HNE ADDUCTS WITH PROTEINS IN THE INSULIN SIGNALING
CASCADES
The regulation of insulin signaling starts with the binding of
insulin to its receptor, whose tyrosyl residues are rapidly phos-
phorylated. This permits the recruitment of adaptor proteins,
such as insulin receptor substrates (IRSs) and Src homology-
2-containing (Shc) proteins, which transmit the insulin signal
down the PI3K cascade for glucose, lipid, and protein metabolism
and the MAPK cascade for cell proliferation and differentiation
(Saltiel and Kahn, 2001; Van Obberghen et al., 2001; White,
2002; Taniguchi et al., 2006). Reductions in the levels of IRSs
and insulin-induced IRSs and a decrease in insulin receptor β
phosphorylation were observed upon exposure to HNE at non-
toxic concentrations (Demozay et al., 2008). Such effects could be
due to the formation of HNE-IRS adducts, likely impairing IRS
function and favoring IRS degradation. The downstream signal-
ing cascades, involving PI3K and protein kinase B (PKB), were
also down-regulated upon exposure to HNE, which resulted in
blunted metabolic responses. The Authors of this study hypoth-
esized that HNE build-up in diabetic rats (due to increased lipid
peroxidation and altered clearance of its products by detoxifying
enzymes) might be a cause of signaling dysfunction, hindering
insulin action.
CONCLUSIONS
The adducts of reactive aldehydes with membrane proteins par-
ticipate in physiological, as well as pathological processes and
can determine variable functional consequences, in relation with
the protein targets of adduction and their functional roles.
Polyclonal and monoclonal antibodies directed against protein-
bound aldehyde adducts have been of great help in exploring the
aldehyde-related modifications of the cell proteome, while mass
spectrometry-based techniques have been playing a key role in
elucidating the stoichiometry and sites of covalent protein mod-
ification with reactive aldehydes. Nonetheless, the inventory of
aldehyde-modified membrane proteins detected so far is prob-
ably still largely incomplete, when compared with the plethora
of biological effects displayed by these molecules. Quantitative
technical limitations in the individuation of aldehyde-protein
adducts are being gradually overcome by the increases in sensi-
tivity, molecular specificity and tolerance to impurities of spec-
trometric instrumentation and techniques (Wu and Vogt, 2012).
Current challenges include: (1) characterizing the functional con-
sequences of cell protein modification with aldehydes, which
was not addressed by most redox proteomic studies published
until now. This may involve major efforts of expression, recon-
stitution, modification and activity/interactivity assays of protein
targets of aldehyde modification in vitro, as well as innovative
approaches of protein-specific tracking and functional character-
ization at the cellular level; (2) clarifying the sources, sites and
circumstances of increased lipid peroxidation in cells and the
topological/functional relationships (e.g., in terms of subcellu-
lar compartmentalization and regulation of gene expression and
gene product activity) linking the increased generation of reac-
tive aldehydes with the modifications of specific cell membrane
proteins.
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